Table of Content


Introduction
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Discontinued Products
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones
Appendix



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Abbisko Therapeutics Co Ltd, 2021
Pipeline by Akeso Inc, 2021
Pipeline by Antengene Corp Ltd, 2021
Pipeline by Aprilbio Co Ltd, 2021
Pipeline by Arcus Biosciences Inc, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Aurigene Discovery Technologies Ltd, 2021
Pipeline by BioArdis LLC, 2021
Pipeline by BrightPath Biotherapeutics Co Ltd, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by Corvus Pharmaceuticals Inc, 2021
Pipeline by Eternity Bioscience Inc, 2021
Pipeline by Evotec SE, 2021
Pipeline by Harbour BioMed (Guangzhou) Co Ltd, 2021
Pipeline by I-Mab, 2021
Pipeline by Incyte Corp, 2021
Pipeline by Innate Pharma SA, 2021
Pipeline by Innovent Biologics Inc, 2021
Pipeline by InteRNA Technologies BV, 2021
Pipeline by iOnctura SA, 2021
Pipeline by Jacobio Pharmaceuticals Group Co Ltd, 2021
Pipeline by Les Laboratoires Servier SAS, 2021
Pipeline by Ligand Pharmaceuticals Inc, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Novartis AG, 2021
Pipeline by ORIC Pharmaceuticals Inc, 2021
Pipeline by Phanes Therapeutics Inc, 2021
Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021
Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2021
Pipeline by Shanghai GeneChem Co Ltd, 2021
Pipeline by Shanghai Henlius Biotech Inc, 2021
Pipeline by Symphogen A/S, 2021
Pipeline by Trican Biotechnology Co Ltd, 2021
Pipeline by Verseon Corp, 2021
Pipeline by Zhejiang Borui Biopharmaceutical Co Ltd, 2021
Dormant Projects, 2021
Discontinued Products, 2021